<p>RNS 编号：5047U Glazer Capital, LLC2025 年 8 月 8 日</p>
<p>表格 8.3</p>
<p>公开持仓披露/交易披露</p>
<p>由持有相关证券 1% 或以上权益的个人</p>
<p>收购守则第 8.3 条（&#34;守则&#34;）</p>
<p>1. 关键信息</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露持仓/交易的个人身份：</td>
<td>Glazer Capital, LLC</td>
</tr>
<tr>
<td>(b) 如果与 1(a) 不同，权益和空头头寸的所有者或控制者：</td>
<td></td>
</tr>
<tr>
<td>提名或车辆公司的名称不足以满足要求</td>
<td>不适用</td>
</tr>
<tr>
<td>(c) 本表格所涉及的要约方/被要约方的名称：</td>
<td></td>
</tr>
<tr>
<td>每个要约方/被要约方使用单独的表格</td>
<td>Assura plc</td>
</tr>
<tr>
<td>(d) 如果是与要约方/被要约方相关的豁免基金经理，请说明并指定要约方/被要约方的身份：</td>
<td>不适用</td>
</tr>
<tr>
<td>(e) 持仓日期/交易日期：</td>
<td>2025 年 8 月 7 日</td>
</tr>
<tr>
<td>(f) 披露者是否曾经披露过，或今天是否在根据守则披露与本次要约的任何其他方有关的信息？</td>
<td>Primary Health Properties plc</td>
</tr>
</tbody>
</table>
<p>2. 披露者的持仓</p>
<p>(a) 与披露相关的要约方或被要约方的相关证券的权益和空头头寸（如有）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别：</td>
<td>10 便士普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>权益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 衍生品（除期权外）：</td>
<td>39,084,343</td>
<td>1.20%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 购买/出售的期权和协议：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计：</td>
<td>39,084,343</td>
<td>1.20%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>所有权益和所有空头头寸均应披露。</p>
<p>任何开放的衍生品或期权头寸，或购买或出售相关证券的协议的详细信息应在补充表格 8（开放头寸）中提供。</p>
<p>(b) 认购新证券的权利（包括董事和其他高管的期权）</p>
<ul>
<li>相关证券类别：</li>
<li>详细信息，包括相关权利的性质和相关百分比：</li>
</ul>
<p>如果在 1(c) 中提到的要约方或被要约方的多个类别的相关证券中有持仓或认购权需要披露，请为每个额外类别的相关证券复制表格 2(a) 或 (b)（视情况而定）。</p>
<p>3. 披露者的交易（如有）</p>
<p>(a) 购买和销售</p>
<ul>
<li>相关证券类别</li>
<li>购买/销售</li>
<li>证券数量</li>
<li>每单位价格</li>
</ul>
<p>(b) 衍生品交易（除期权外）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>10 便士普通股</td>
</tr>
<tr>
<td>产品描述</td>
<td></td>
</tr>
<tr>
<td>例如：差价合约</td>
<td>总回报股权掉期</td>
</tr>
<tr>
<td>交易性质</td>
<td></td>
</tr>
<tr>
<td>例如：开立/平仓多头/空头头寸，增加/减少多头/空头头寸</td>
<td>减少多头头寸</td>
</tr>
<tr>
<td>参考证券数量</td>
<td>15,398,255</td>
</tr>
<tr>
<td>每单位价格</td>
<td>0.49 英镑</td>
</tr>
</tbody>
</table>
<p>(c) 关于现有证券的期权交易</p>
<p>(i) 写入、出售、购买或变更</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如：看涨期权</li>
<li>写入、购买、出售、变更等。</li>
<li>与期权相关的证券数量</li>
<li>每单位行使价格</li>
<li>类型，例如：美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付/收到的期权费用</li>
</ul>
<p>(ii) 行使</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如：看涨期权</li>
<li>证券数量</li>
<li>每单位行使价格</li>
</ul>
<p>(d) 其他交易（包括认购新证券）</p>
<ul>
<li>相关证券类别</li>
<li>交易性质，例如：认购、转换</li>
<li>详细信息</li>
<li>每单位价格（如适用）</li>
</ul>
<p>所有价格和其他货币金额的货币应予以说明。</p>
<p>如果在 1(c) 中提到的要约方或被要约方的多个类别的相关证券中有交易，请为每个额外类别的相关证券复制表格 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
<p>4. 其他信息</p>
<p>(a) 赔偿和其他交易安排</p>
<ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使披露者与要约方或与要约方一致行动的任何人进行交易或避免交易：如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
<p>(b) 与期权或衍生品有关的协议、安排或理解</p>
<ul>
<li>披露者与任何其他人之间的任何协议、安排或理解的详细信息，无论是正式还是非正式，涉及：(i) 任何相关证券在任何期权下的投票权；或 (ii) 任何衍生品所参考的任何相关证券的投票权或未来的收购或处置：如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
<p>(c) 附件</p>
<ul>
<li>是否附有补充表格 8（开放头寸）？</li>
<li>否</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>2025 年 8 月 8 日</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Anny Kim</td>
</tr>
<tr>
<td>电话号码：</td>
<td>212-804-9971</td>
</tr>
</tbody>
</table>
<p>根据守则第 8 条的公开披露必须向监管信息服务机构进行，并且还必须通过电子邮件发送至监控小组，邮箱为 monitoring@disclosure.org.uk。该小组的市场监测单位可就守则的交易披露要求提供咨询，电话为 +44 (0) 20 7638 0129。</p>
<p>守则可在小组网站 www.thetakeoverpanel.org.uk 上查看。</p>
<p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址来确认您是否遵守条款和条件，分析您如何与本通信中包含的信息互动，并将此分析以匿名方式与他人分享，作为我们商业服务的一部分。有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参阅我们的隐私政策。END RETPRMMTMTIMTLA</p>

<p>Glazer Capital, LLC 披露了其在 Assura plc 的持仓，报告拥有 39,084,343 相关证券，占该公司 1.20%。该披露是根据收购守则第 8.3 条进行的，持仓截至 2025 年 8 月 7 日。报告还提到，涉及 15,398,255 证券的多头头寸减少，价格为 0.49 英镑。没有披露其他协议或安排。该公告由 Anny Kim 于 2025 年 8 月 8 日发布</p>

<p>RNS Number : 5047U Glazer Capital, LLC 08 August 2025</p>
<div class="lb-trans"><p>RNS 编号：5047U Glazer Capital, LLC2025 年 8 月 8 日</p>
</div><p>FORM 8.3</p>
<div class="lb-trans"><p>表格 8.3</p>
</div><p>PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY</p>
<div class="lb-trans"><p>公开持仓披露/交易披露</p>
</div><p>A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE</p>
<div class="lb-trans"><p>由持有相关证券 1% 或以上权益的个人</p>
</div><p>Rule 8.3 of the Takeover Code (the &#34;Code&#34;)</p>
<div class="lb-trans"><p>收购守则第 8.3 条（&#34;守则&#34;）</p>
</div><p>1. KEY INFORMATION</p>
<div class="lb-trans"><p>1. 关键信息</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Identity of the person whose positions/dealings are being disclosed:</td>
<td>Glazer Capital, LLC</td>
</tr>
<tr>
<td>(b) Owner or controller of interests and short positions disclosed, if different from 1(a):<br/>The naming of nominee or vehicle companies is insufficient</td>
<td>N/A</td>
</tr>
<tr>
<td>(c) Name of offeror/offeree in relation to whose relevant securities this form relates:<br/>Use a separate form for each offeror/offeree</td>
<td>Assura plc</td>
</tr>
<tr>
<td>(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:</td>
<td>N/A</td>
</tr>
<tr>
<td>(e) Date position held/dealing undertaken:</td>
<td>August 7, 2025</td>
</tr>
<tr>
<td>(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?</td>
<td>Primary Health Properties plc</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露持仓/交易的个人身份：</td>
<td>Glazer Capital, LLC</td>
</tr>
<tr>
<td>(b) 如果与 1(a) 不同，权益和空头头寸的所有者或控制者：</td>
<td></td>
</tr>
<tr>
<td>提名或车辆公司的名称不足以满足要求</td>
<td>不适用</td>
</tr>
<tr>
<td>(c) 本表格所涉及的要约方/被要约方的名称：</td>
<td></td>
</tr>
<tr>
<td>每个要约方/被要约方使用单独的表格</td>
<td>Assura plc</td>
</tr>
<tr>
<td>(d) 如果是与要约方/被要约方相关的豁免基金经理，请说明并指定要约方/被要约方的身份：</td>
<td>不适用</td>
</tr>
<tr>
<td>(e) 持仓日期/交易日期：</td>
<td>2025 年 8 月 7 日</td>
</tr>
<tr>
<td>(f) 披露者是否曾经披露过，或今天是否在根据守则披露与本次要约的任何其他方有关的信息？</td>
<td>Primary Health Properties plc</td>
</tr>
</tbody>
</table>
</div><p>2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE</p>
<div class="lb-trans"><p>2. 披露者的持仓</p>
</div><p>(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)</p>
<div class="lb-trans"><p>(a) 与披露相关的要约方或被要约方的相关证券的权益和空头头寸（如有）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security:</td>
<td>10p ordinary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interests</td>
<td>Short positions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>%</td>
<td>Number</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>(1) Relevant securities owned and/or controlled:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) Derivatives (other than options):</td>
<td>39,084,343</td>
<td>1.20%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) Options and agreements to purchase/sell:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL:</td>
<td>39,084,343</td>
<td>1.20%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别：</td>
<td>10 便士普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>权益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 衍生品（除期权外）：</td>
<td>39,084,343</td>
<td>1.20%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 购买/出售的期权和协议：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计：</td>
<td>39,084,343</td>
<td>1.20%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>All interests and all short positions should be disclosed.</p>
<div class="lb-trans"><p>所有权益和所有空头头寸均应披露。</p>
</div><p>Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).</p>
<div class="lb-trans"><p>任何开放的衍生品或期权头寸，或购买或出售相关证券的协议的详细信息应在补充表格 8（开放头寸）中提供。</p>
</div><p>(b) Rights to subscribe for new securities (including directors' and other executive options)</p>
<div class="lb-trans"><p>(b) 认购新证券的权利（包括董事和其他高管的期权）</p>
</div><ul>
<li>Class of relevant security in relation to which subscription right exists:</li>
<li>Details, including nature of the rights concerned and relevant percentages:</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别：</li>
<li>详细信息，包括相关权利的性质和相关百分比：</li>
</ul>
</div><p>If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.</p>
<div class="lb-trans"><p>如果在 1(c) 中提到的要约方或被要约方的多个类别的相关证券中有持仓或认购权需要披露，请为每个额外类别的相关证券复制表格 2(a) 或 (b)（视情况而定）。</p>
</div><p>3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE</p>
<div class="lb-trans"><p>3. 披露者的交易（如有）</p>
</div><p>(a) Purchases and sales</p>
<div class="lb-trans"><p>(a) 购买和销售</p>
</div><ul>
<li>Class of relevant security</li>
<li>Purchase/sale</li>
<li>Number of securities</li>
<li>Price per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>购买/销售</li>
<li>证券数量</li>
<li>每单位价格</li>
</ul>
</div><p>(b) Derivatives transactions (other than options)</p>
<div class="lb-trans"><p>(b) 衍生品交易（除期权外）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security</td>
<td>10p ordinary</td>
</tr>
<tr>
<td>Product description<br/>e.g. CFD</td>
<td>Total return equity swaps</td>
</tr>
<tr>
<td>Nature of dealing<br/>e.g. opening/closing a long/short position, increasing/reducing a long/short position</td>
<td>Reducing a long position</td>
</tr>
<tr>
<td>Number of reference securities</td>
<td>15,398,255</td>
</tr>
<tr>
<td>Price per unit</td>
<td>0.49 GBP</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>10 便士普通股</td>
</tr>
<tr>
<td>产品描述</td>
<td></td>
</tr>
<tr>
<td>例如：差价合约</td>
<td>总回报股权掉期</td>
</tr>
<tr>
<td>交易性质</td>
<td></td>
</tr>
<tr>
<td>例如：开立/平仓多头/空头头寸，增加/减少多头/空头头寸</td>
<td>减少多头头寸</td>
</tr>
<tr>
<td>参考证券数量</td>
<td>15,398,255</td>
</tr>
<tr>
<td>每单位价格</td>
<td>0.49 英镑</td>
</tr>
</tbody>
</table>
</div><p>(c) Options transactions in respect of existing securities</p>
<div class="lb-trans"><p>(c) 关于现有证券的期权交易</p>
</div><p>(i) Writing, selling, purchasing or varying</p>
<div class="lb-trans"><p>(i) 写入、出售、购买或变更</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Writing, purchasing, selling, varying etc.</li>
<li>Number of securities to which option relates</li>
<li>Exercise price per unit</li>
<li>Typee.g. American, European etc.</li>
<li>Expiry date</li>
<li>Option money paid/ received per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如：看涨期权</li>
<li>写入、购买、出售、变更等。</li>
<li>与期权相关的证券数量</li>
<li>每单位行使价格</li>
<li>类型，例如：美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付/收到的期权费用</li>
</ul>
</div><p>(ii) Exercising</p>
<div class="lb-trans"><p>(ii) 行使</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product descriptione.g. call option</li>
<li>Number of securities</li>
<li>Exercise price per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如：看涨期权</li>
<li>证券数量</li>
<li>每单位行使价格</li>
</ul>
</div><p>(d) Other dealings (including subscribing for new securities)</p>
<div class="lb-trans"><p>(d) 其他交易（包括认购新证券）</p>
</div><ul>
<li>Class of relevant security</li>
<li>Nature of dealinge.g. subscription, conversion</li>
<li>Details</li>
<li>Price per unit (if applicable)</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>交易性质，例如：认购、转换</li>
<li>详细信息</li>
<li>每单位价格（如适用）</li>
</ul>
</div><p>The currency of all prices and other monetary amounts should be stated.</p>
<div class="lb-trans"><p>所有价格和其他货币金额的货币应予以说明。</p>
</div><p>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</p>
<div class="lb-trans"><p>如果在 1(c) 中提到的要约方或被要约方的多个类别的相关证券中有交易，请为每个额外类别的相关证券复制表格 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
</div><p>4. OTHER INFORMATION</p>
<div class="lb-trans"><p>4. 其他信息</p>
</div><p>(a) Indemnity and other dealing arrangements</p>
<div class="lb-trans"><p>(a) 赔偿和其他交易安排</p>
</div><ul>
<li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使披露者与要约方或与要约方一致行动的任何人进行交易或避免交易：如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
</div><p>(b) Agreements, arrangements or understandings relating to options or derivatives</p>
<div class="lb-trans"><p>(b) 与期权或衍生品有关的协议、安排或理解</p>
</div><ul>
<li>Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>披露者与任何其他人之间的任何协议、安排或理解的详细信息，无论是正式还是非正式，涉及：(i) 任何相关证券在任何期权下的投票权；或 (ii) 任何衍生品所参考的任何相关证券的投票权或未来的收购或处置：如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
</div><p>(c) Attachments</p>
<div class="lb-trans"><p>(c) 附件</p>
</div><ul>
<li>Is a Supplemental Form 8 (Open Positions) attached?</li>
<li>NO</li>
</ul>
<div class="lb-trans"><ul>
<li>是否附有补充表格 8（开放头寸）？</li>
<li>否</li>
</ul>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure:</td>
<td>August 8, 2025</td>
</tr>
<tr>
<td>Contact name:</td>
<td>Anny Kim</td>
</tr>
<tr>
<td>Telephone number:</td>
<td>212-804-9971</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>2025 年 8 月 8 日</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Anny Kim</td>
</tr>
<tr>
<td>电话号码：</td>
<td>212-804-9971</td>
</tr>
</tbody>
</table>
</div><p>Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0) 20 7638 0129.</p>
<div class="lb-trans"><p>根据守则第 8 条的公开披露必须向监管信息服务机构进行，并且还必须通过电子邮件发送至监控小组，邮箱为 monitoring@disclosure.org.uk。该小组的市场监测单位可就守则的交易披露要求提供咨询，电话为 +44 (0) 20 7638 0129。</p>
</div><p>The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.</p>
<div class="lb-trans"><p>守则可在小组网站 www.thetakeoverpanel.org.uk 上查看。</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RETPRMMTMTIMTLA</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址来确认您是否遵守条款和条件，分析您如何与本通信中包含的信息互动，并将此分析以匿名方式与他人分享，作为我们商业服务的一部分。有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参阅我们的隐私政策。END RETPRMMTMTIMTLA</p>
</div>

REG - Glazer Capital, LLC Assura plc Primary Health Properties - 表格 8.3 - Assura plc